Factor XI inhibitors for the prevention of cardiovascular disease: A new therapeutic approach on the horizon?
Abelacimab
Anticoagulants
Anticoagulation
Asundexian
Atrial fibrillation
Factor XI
Factor XI inhibitors
Ischemic stroke
Milvexian
Journal
Blood reviews
ISSN: 1532-1681
Titre abrégé: Blood Rev
Pays: England
ID NLM: 8708558
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
19
06
2023
revised:
06
08
2023
accepted:
08
08
2023
medline:
6
12
2023
pubmed:
15
8
2023
entrez:
14
8
2023
Statut:
ppublish
Résumé
Anticoagulant drugs that are currently used to prevent and/or treat thrombosis have some limitations that hinder their ability to meet specific clinical requirements. While these drugs effectively reduce the rates of thrombotic events, they simultaneously increase the risk of bleeding. Moreover, their risk-to-benefit balance is problematic in some patients, such as those with severe chronic kidney disease or those at high bleeding risk. A novel anticoagulation method, FXI inhibition has emerged as a promising alternative. It demonstrates a strong rationale for the prevention and treatment of venous thromboembolism and the potential fulfillment of unmet clinical needs in the cardiovascular field. A number of FXI inhibitors are currently undergoing clinical investigation. The objective of this review is to provide an overview of early results of research on FXI inhibitors in the cardiovascular setting, offering valuable insights into their potential role in shaping the future of anticoagulation.
Identifiants
pubmed: 37580207
pii: S0268-960X(23)00080-2
doi: 10.1016/j.blre.2023.101119
pii:
doi:
Substances chimiques
Factor XI
9013-55-2
Anticoagulants
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
101119Informations de copyright
Copyright © 2023 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest Santagata D. MD: no conflict to disclose. Professor Donadini M.P. MD, PhD: no conflict to disclose. Professor Ageno W. MD: Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Bayer, BMS/Pfizer, Viatris, Leo Pharma, Sanofi. Participation on a Data Safety Monitoring Board or Advisory Board for Bayer, Norgine, Leo Pharma, Sanofi, Techdow.